We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (305)
- Scheduling (national classification system) (160)
- Advertising (25)
- Safety monitoring and information (23)
- COVID-19 (11)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Clinical trials (4)
- Compliance and enforcement (4)
- Shortages and supply disruptions (3)
- Legislation (2)
- Breast implant hub (1)
- Cosmetics (1)
- Import and export (1)
- Manufacturing (1)
- Prescription opioids hub (1)
Search
574 result(s) found, displaying 451 to 475
-
Meeting statementsACM 2 meeting statement has been published
-
Meeting statementsACM 3 meeting statement has been published
-
Meeting statementsACM 4 meeting statement has been published
-
Scheduling delegates' interim decisions and invitation for further comment: ACCS/ACMS, November 2017
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 5 March 2018 -
Scheduling decisions (final)Scheduling delegates' final decisions: NCEs, January 2017 now published
-
Meeting statementsACV 1 meeting statement has been published
-
Meeting statementsACV 2 meeting statement has been published
-
Corporate reportsThis document reflects the evidence supporting the use of medicinal cannabis in treating chronic pain and the recommendations of the Chronic Pain Working Group
-
Scheduling decisions (final)Final decisions and reasons for matters referred to ACCS#20, ACMS #21 (July 2017 meetings) and Joint ACCS-ACMS #15 and #16 (March and July 2017meetings).
-
Meeting statementsAdvisory Committee on Biologicals (ACB), Meeting 7 statement
-
Meeting statementsAdvisory Committee on Biologicals (ACB), Meeting 8 statement
-
Meeting statementsAdvisory Committee on Biologicals (ACB), Meeting 9 statement
-
Meeting statementsAdvisory Committee on Biologicals (ACB), Meeting 10 statement
-
Meeting statementsAustralian Influenza Vaccine Committee (AIVC) recommendations
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closing date: 3 October 2017
-
Meeting statementsACM 1 meeting statement has been published
-
Corporate reportsTGA Stakeholder Survey 2016-17 - questions and answers
-
Scheduling decisions (final)Final decisions for medicines and chemicals referred to March 2017 scheduling meetings (ACMS #20, ACCS #19 and Joint ACMS-ACCS #15) and NCEs.
-
Scheduling decisions (final)New Chemical Entity (NCE) delegate's final decision and reasons for decision for brexpiprazole
-
Scheduling decisions (interim)Interim decisions and invitation for further comment. Closed: 31 May 2017
-
Scheduling decisions (final)Delegate-only final decisions to amend the Poisons Standard not referred to an expert advisory committee.
-
Corporate reportsThe TGA's scientific review on the safety of nanoparticles in sunscreens.
-
Scheduling decisions (final)Q&A about changes to the scheduling of codeine.
-
Meeting statementsAdvisory Committee on Prescription Medicines, meeting statement
-
Meeting statementsAdvisory Committee on Prescription Medicines, meeting statement